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Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal anti-
body, enhances T-cell and natural killer-cell antitumor activity in preclinical models,
and may enhance cytotoxic activity of rituximab. Here we report results in patients
with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lym-
phoma (FL), and other B-cell lymphomas, in phase 1 studies evaluating urelumab
alone (NCT01471210) or combined with rituximab (NCT01775631). Sixty patients
received urelumab (0.3 mg/kg IV Q3W, 8 mg IV Q3W, or 8 mg IV Q6W); 46 received
urelumab (0.1 mg/kg, 0.3 mg/kg, or 8 mg IV Q3W) plus rituximab 375 mg/m2 IV
QW. The maximum tolerated dose (MTD) of urelumab was determined to be
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0.1 mg/kg or 8 mg Q3W after a single event of potential drug-induced liver injury
occurred with urelumab 0.3 mg/kg. Treatment-related AEs were reported in 52%
(urelumab: grade 3/4, 15%) and 72% (urelumab + rituximab: grade 3/4, 28%); three
led to discontinuation (grade 3 increased AST, grade 4 acute hepatitis [urelumab];
one death from sepsis syndrome [urelumab plus rituximab]). Objective response
rates/disease control rates were 6%/19% (DLBCL, n = 31), 12%/35% (FL, n = 17),
and 17%/42% (other B-cell lymphomas, n = 12) with urelumab and 10%/24%
(DLBCL, n = 29) and 35%/71% (FL, n = 17) with urelumab plus rituximab. Durable
remissions in heavily pretreated patients were achieved; however, many were
observed at doses exceeding the MTD. These data show that urelumab alone or in
combination with rituximab demonstrated manageable safety in B-cell lymphoma, but
the combination did not enhance clinical activity relative to rituximab alone or other
current standard of care.
1 | INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma
(FL) comprise approximately half of all cases of non-Hodgkin lym-
phoma (NHL).1 DLBCL, the most common type of NHL (≈30% of
cases), is a heterogeneous, aggressive lymphoma,1,2 whereas FL is an
indolent lymphoma accounting for approximately 22% of NHL cases.1
The introduction of chemoimmunotherapy, including high-dose che-
motherapy regimens in combination with the CD20-directed mono-
clonal antibody rituximab, has improved outcomes in patients with
DLBCL and FL.1,3,4 The majority of patients with DLBCL can be cured
with first-line therapy; however, approximately one-third of all
patients are refractory to treatment or relapse afterward.2,3 In con-
trast, most patients with FL experience disease progression (PD) after
treatment, with recurrent relapses characterized by shorter remissions
with each successive line of therapy.5 Patients with FL who progress
within 24 months of diagnosis after first-line chemoimmunotherapy
have significantly shorter overall survival.6 Patients with relapsed FL
may also become refractory to chemoimmunotherapy or undergo his-
tological transformation to a more aggressive NHL subtype.5,7 Prog-
nosis remains poor for patients with relapsed or refractory (R/R)
DLBCL or FL2,5,6; therefore, novel, more effective regimens are
needed for these R/R populations. Therapeutic blockade of check-
point pathway inhibitory receptors has demonstrated efficacy in mul-
tiple malignancies, including in patients with R/R classic Hodgkin
lymphoma.8,9 However, an unmet need remains in patients with R/R
B-cell lymphomas, as variable clinical benefit has been observed with
single-agent checkpoint pathway blockade.10-12
Additional immunotherapy approaches targeting immunoregula-
tory receptors, including agonist antibodies against costimulatory
molecules such as CD137 (4-1BB), may enhance antitumor immu-
nity in patients with cancer.13-15 Signaling via CD137, a
costimulatory member of the tumor necrosis factor receptor (TNFR)
superfamily, can lead to induction of cytokines, protection from
activation-induced cell death, and upregulation of cytotoxic T-cell
activity and may also reduce the infiltration of regulatory T cells into
tumors.14-19 In murine lymphoma models, agonist anti-CD137 treat-
ment led to long-lasting antitumor activity mediated by natural killer
and CD8 T cells.19
Urelumab is a fully human, non-ligand binding, CD137 agonist
immunoglobulin-γ 4 (IgG4) monoclonal antibody, that was evaluated
as monotherapy or in combination with other immunotherapies or
targeted agents in multiple phase 1/2 clinical trials.16,20-22 In an inte-
grated safety analysis of three urelumab monotherapy studies
(NCT00309023, NCT00612664, and NCT01471210), urelumab doses
≥1 mg/kg every 3 weeks (Q3W) were shown to be associated with
more frequent transaminitis.16 Therefore, in these and all subsequent
studies of urelumab, a lower dose range (<1 mg/kg Q3W) was evalu-
ated, and liver toxicities were closely monitored. Results from
urelumab monotherapy and combination studies suggested limited
clinical activity in patients with advanced solid tumors; however, pre-
liminary activity was observed in patients with lymphoma.20,21 Here,
we report final results in patients with R/R DLBCL, FL, and other
types of B-cell NHL treated in two phase 1 studies evaluating
urelumab alone or in combination with rituximab (NCT01471210;
NCT01775631).
2 | METHODS
2.1 | Study design and treatments
NCT01471210 (CA186-011) was an open-label, phase 1 study evalu-
ating the safety, pharmacokinetics (PK), immunoregulatory activity,
and antitumor activity of urelumab in patients with advanced and/or
metastatic solid tumors and R/R B-cell NHL across 22 active sites in
France, Germany, Spain, and the United States. The results from
expansion cohorts in patients with R/R B-cell NHL are reported here.
Patients with DLBCL, FL, or other types of B-cell NHL were treated
with urelumab 0.3 mg/kg intravenously (IV) Q3W for ≤8 doses or
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urelumab 8 mg IV Q3W (≤8 doses; equivalent to 0.1 mg/kg in an
80-kg patient) or Q6W (≤4 doses; Figure S1).
NCT01775631 (CA186-017) was an open-label, phase 1b study
evaluating the safety, PK, pharmacodynamics, and antitumor activity
of urelumab in combination with rituximab in patients with R/R B-cell
NHL across 12 active sites in the United States. Patients with DLBCL
or FL were treated with urelumab 0.3 mg/kg, 0.1 mg/kg, or 8 mg IV
Q3W (≤8 doses) + rituximab 375 mg/m2 IV QW (≤8 doses; adminis-
tered during the first 4 weeks of each 12-week cycle) during escala-
tion and urelumab 8 mg IV Q3W (≤8 doses) plus rituximab 375 mg/
m2 IV QW (≤8 doses; administered during the first 4 weeks of each
12-week cycle) during expansion (Figure S1).
In both studies, patients were treated until PD, unacceptable tox-
icity, or withdrawal of consent. Treatment beyond PD, defined by the
International Working Group (IWG) Response Criteria for NHL,23 was
permitted in patients experiencing clinical benefit without signs of
clinical deterioration or intolerance of therapy per investigator discre-
tion. Patients completing approximately 24 weeks of treatment and
entering follow-up for reasons other than treatment-related toxicity
with ongoing disease control, and subsequent confirmed PD within
12 months of the last dose, were eligible for retreatment for an addi-
tional 24 weeks.
The study protocols were approved by the institutional review
board or independent ethics committee of each participating institu-
tion. The studies were conducted in accordance with the Declaration
of Helsinki and Good Clinical Practice as defined by the International
Conference on Harmonization. All patients provided written informed
consent prior to enrollment.
2.2 | Patients
In CA186-011, eligible patients with B-cell NHL had R/R disease after
≥1 prior line of standard therapy per IWG Response Criteria for
NHL.23 In CA186-017, eligible patients had CD20+ B-cell NHL with
measurable disease per IWG Response Criteria for NHL23 that was
refractory to or had relapsed after ≥1 prior line of standard therapy.
Patients in the expansion phase must have received ≥1 prior multi-
agent chemotherapy regimen and must have had R/R disease after
prior rituximab alone or in combination with chemotherapy. In both
studies, patients had to be aged ≥18 years with an ECOG perfor-
mance status of 0 or 1 and were required to provide pre- and on-
treatment biopsies or fine-needle aspirates.
Patients with central nervous system lymphoma, active autoim-
mune disease (or a documented history of autoimmune disease or a
syndrome that required systemic steroids or immunosuppressive med-
ications), known or suspected HIV or hepatitis (or history of hepatitis),
evidence of active infection, or history of clinically significant cardiac
disease were not eligible for enrollment in either study.
Anticancer therapy, nononcology live viral vaccine therapy (for the
prevention of infectious diseases), surgery (unless minor [ie, biopsies]),
radiotherapy, or the use of immunosuppressive medications or immu-
nosuppressive doses of systemic corticosteroids (doses >10 mg/day of
prednisone or equivalent) or growth-factor treatments were not per-
mitted within 28 days of dosing in either study. Prior treatment with
agents targeting immune checkpoints (eg, programmed death [PD]-1,
programmed death ligand 1 [PD-L1], PD-L2, lymphocyte-activation
gene 3, or cytotoxic T lymphocyte antigen-4) was permitted after a
washout period of >100 days from the last dose in a subset of
patients treated in CA186-011. And, it was permitted only during
the early portion of CA186-017 after a washout period of >28 days;
in the final CA186-017 protocol, prior treatment with checkpoint
pathway inhibitors was prohibited. Prior treatment with agents
targeting T-cell costimulatory pathways (eg, CD137, glucocorticoid-
induced TNFR-related protein, OX40) was not permitted in either
study.
2.3 | Endpoints and assessments
The primary endpoint was safety and tolerability of urelumab
(CA186-011) and urelumab plus rituximab (CA186-017). Secondary
endpoints included PK, immunogenicity, and antitumor activity. Key
exploratory endpoints included pharmacodynamic analyses.
Adverse events (AEs) were assessed during treatment, for
≥60 days after the last dose of urelumab, and for ≥110 days after the
last dose of rituximab according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version 4.0. Determina-
tion of the maximum tolerated dose (MTD) in CA186-011 was based
on the incidence of drug-related dose-limiting toxicities (DLTs) during
the first 9 weeks of therapy. It was defined as the highest dose at
which <33% of patients experienced a DLT and <20% of patients
experienced a hepatic nonhematologic DLT. This was with no event
of Hyʼs law (any drug-related alanine aminotransferase [ALT] or aspar-
tate aminotransferase [AST] > 3 × upper limit of normal [ULN] accom-
panied by concurrent total bilirubin >2 × ULN without cholestasis)
occurring at any time. In CA186-017, the MTD of urelumab plus
rituximab was based on the incidence of DLTs during the first 43 days
of therapy and was defined as the highest dose at which <33% of
patients experienced a DLT, with no event of Hyʼs law occurring at
any time.
Pharmacokinetics and immunogenicity summary statistics were
determined in serum samples collected at baseline, at protocol-
defined time points throughout treatment, at the end of treatment,
and during the follow-up period (30- and 60-day visits only for
urelumab; 30-, 60-, and 120-day visits for rituximab).
Tumor response was evaluated by the investigator per IWG
Response Criteria for NHL23 at baseline, during treatment (every
9 weeks [CA186-011] or every 12 weeks [CA186-017]) until PD or
treatment discontinuation using computed tomography, magnetic res-
onance imaging, or fluorodeoxyglucose positron emission tomography
(PET). In patients with bone marrow involvement at baseline, a bone
marrow biopsy or aspirate was required to confirm a complete
response.
Changes in immune-related gene expression in whole blood (sup-
plemental methods) and serum levels of immune factors during
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treatment were evaluated by quantitative polymerase chain reaction
and quantitative multiplexed immunoassays (Myriad RBM, Austin,
TX), respectively, in samples collected at baseline and at protocol-
specified time points throughout cycles 1 and 2.
2.4 | Statistical analyses
Descriptive statistics were used to characterize baseline demo-
graphics, safety, PK, immunogenicity, and pharmacodynamics.
Clopper-Pearson 95% two-sided confidence intervals were used to
estimate objective response rate (ORR; defined as best response of
complete remission or partial remission) and disease control rate
(DCR; defined as best response of complete remission, partial remis-
sion, or stable disease). Kaplan-Meier methodology was used to esti-
mate duration of response (DOR; defined as the time from the first
response to PD or death. Duration of response was censored at the
last tumor assessment if the patient had not progressed or died at
the time of the analysis), progression-free survival (PFS; defined as
the time from the first dose to PD or death from any cause), and over-
all survival (OS; defined as the time from the first dose to death from
any cause).
All patients who received ≥1 dose of urelumab (CA186-011) or
urelumab plus rituximab (CA186-017) were included in baseline
demographic, safety, and antitumor analyses. For PK, immunogenicity,
and pharmacodynamic analyses, only patients with adequate baseline
and postbaseline PK, immunogenicity, or pharmacodynamic data were
included.
3 | RESULTS
3.1 | Patient population and disposition
A total of 106 patients with R/R B-cell NHL were treated with
urelumab (n = 60: DLBCL, n = 31; FL, n = 17; other B-cell lymphomas,
n = 12) or urelumab plus rituximab (n = 46: DLBCL, n = 29; FL, n = 17)
(Table 1). Median age ranged from 52 to 76 years across dose cohorts
in both studies. Patients were mostly male (59%) and predominantly
white (93%). Most patients with DLBCL had received ≥3 prior sys-
temic therapies (urelumab monotherapy, 52%; urelumab plus
rituximab, 69%); fewer patients with FL (urelumab monotherapy, 29%;
urelumab plus rituximab, 53%) and other types of B-cell NHL
(urelumab monotherapy, 42%) had received ≥3 prior systemic thera-
pies (Table 1).
At the time of the final database locks (CA0186-011, June
3, 2016; CA0186-017, October 4, 2016), 101 patients had discon-
tinued treatment with urelumab (n = 57; 95%) or urelumab plus
rituximab (n = 44; 96%), primarily due to PD (urelumab, 75%;
urelumab plus rituximab, 63%; Table S1). Median durations of treat-
ment were 9.4 weeks (range, 3.0-97.3 weeks) with urelumab and
9.2 weeks (range, 3.0-67.0 weeks) with urelumab plus rituximab
(Table S2).
3.2 | Safety
The MTD was determined to be urelumab 0.1 mg/kg or 8 mg Q3W
after a single event of potential drug-induced liver injury (pDILI)
occurred in a patient treated with urelumab 0.3 mg/kg in study
CA186-011. Following this event, enrollment into the 0.3 mg/kg dose
level was halted, and all subsequent patients enrolled into the
CA186-011 and CA186-017 studies were treated with lower doses.
In CA186-011, dosing was reduced to 0.1 mg/kg for all ongoing
patients and to 8 mg Q3W or Q6W for all subsequent patients. In
CA186-017, dosing was reduced to 0.1 mg/kg or 8 mg Q3W.
With urelumab monotherapy, treatment-related AEs (TRAEs)
were reported in 52% of patients (grade 3/4, 15%) (Table 2), with the
most frequent TRAEs (≥10%, any grade) being fatigue (any grade,
15%; no grade 3/4 events) and neutropenia (any grade, 12%; grade
3/4, 12%). A higher frequency of any-grade TRAEs was observed with
urelumab 0.3 mg/kg (any grade, 80%; grade 3/4, 10%) compared with
urelumab 8 mg Q3W (any grade, 48%; grade 3/4, 24%) and urelumab
8 mg Q6W (any grade, 44%; grade 3/4, 8%). The TRAEs leading to dis-
continuation of urelumab monotherapy included grade 3 increased
AST (n = 1) and grade 4 acute hepatitis (n = 1). No treatment-related
deaths were reported.
With urelumab plus rituximab, 72% of patients experienced a
TRAE (grade 3/4, 28%; Table 2), with the most frequently reported
events (≥10% of any grade) being fatigue (any grade, 20%; grade
3/4, 2%), increased AST (any grade, 15%; no grade 3/4 events),
increased ALT (any grade, 13%; grade 3/4, 2%), neutropenia (any
grade, 13%; grade 3/4, 11%), thrombocytopenia (any grade, 11%;
grade 3/4, 4%), and nausea (any grade, 11%; no grade 3/4 events).
One patient treated with urelumab 0.3 mg/kg plus rituximab died
from treatment-related sepsis syndrome/cytokine release syndrome.
This event occurred in a patient with bulky, rituximab-refractory FL
who had initiated treatment with urelumab 0.3 mg/kg plus rituximab
32 days after progressing on nivolumab. Lymphadenopathy began to
regress rapidly in this patient prior to death. Laboratory findings
included grade 4 transaminase elevations, grade 1 hyperbilirubinemia,
and elevations in serum cytokines including interleukin (IL)-6, IL-10,
TNFα, and monocyte chemoattractant protein-1; a postmortem
examination revealed moderate hepatitis and lymph nodes showing
necrotic tumor largely replaced by CD3+ T cells, fibrosis, and
macrophages.
3.3 | Pharmacokinetics
Urelumab PK parameters increased proportionately with dose and
were not altered substantially when urelumab was combined with
rituximab (Table S3). Following a 1-hour IV infusion, maximum con-
centrations of urelumab were reached at a median time of 1.17 to
2.00 hours with urelumab monotherapy and 2.33 to 3.00 hours with
urelumab plus rituximab. The geometric mean maximum concentra-
tion (Cmax) of urelumab was similar in the 0.1 mg/kg and 8 mg flat-
dose treatment groups in both studies (Cmax, 2.065 μg/mL with
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urelumab 0.1 mg/kg compared with 2.78 and 2.18 μg/mL with
urelumab 8 mg Q3W, and 2.12 μg/mL with urelumab 8 mg Q6W) and
increased approximately 3-fold in the 0.3 mg/kg treatment groups
(Cmax, 6.025 and 8.15 μg/mL).
3.4 | Immunogenicity
Sixteen percent of patients treated with urelumab 8 mg Q3W mon-
otherapy, 16% of patients treated with urelumab 8 mg Q6W mon-
otherapy, and 30% of patients treated with urelumab 0.3 mg/kg
monotherapy were antidrug antibody (ADA) positive after treatment
(Table S4). Overall, ADA positivity did not appear to affect urelumab
safety. No patients were ADA positive after treatment with urelumab
plus rituximab.
3.5 | Efficacy
With urelumab monotherapy, ORR and DCR were respectively 6%
and 19% in patients with DLBCL (n = 31), 12% and 35% in patients
with FL (n = 17), and 17% and 42% in patients with other types of B-
cell NHL (n = 12; Table 3). Half of the responses occurred in patients
treated with urelumab 0.3 mg/kg, which exceeded what was subse-
quently determined to be the MTD. Median DOR was not reached in
patients with DLBCL or FL; however, in patients with other types of
B-cell NHL, median DOR was 18.1 weeks (Table 3). In the 31 patients
with DLBCL treated with urelumab monotherapy, median PFS was
8.1 weeks, and median OS was 45.6 weeks (Table 4). In the
17 patients with FL treated with urelumab monotherapy, median PFS
was 8.9 weeks, and median OS was not reached. In patients with
other types of B-cell NHL (n = 12), median PFS was 13.4 weeks, and
median OS was not reached.
With urelumab plus rituximab, ORR and DCR were respectively
10% and 24% in patients with DLBCL (n = 29) and 35% and 71% in
patients with FL (n = 17; Table 3); responses were observed across all
doses. Median DOR was not reached in patients with DLBCL or FL
treated with the combination (Table 3). In the 29 patients with DLBCL
treated with urelumab plus rituximab, median PFS was 9.0 weeks, and
median OS was 23.9 weeks (Table 4). In the 17 patients with FL
treated with the combination, median PFS was 40.4 weeks, and
median OS was not reached.
Several patients achieved durable partial or complete remissions
or stable disease with urelumab as monotherapy or in combination
with rituximab. One patient with DLBCL treated with urelumab 8 mg
Q6W maintained a partial remission with a PFS of approximately
18 months prior to death at age 84 due to metastatic prostate cancer
as second malignancy. Another patient with DLBCL treated with
urelumab 8 mg Q3W plus rituximab was alive at the last follow-up
(July 2019), with stable disease for >55 months without subsequent
treatment; since the end of study, this patientʼs liver lesion has
become smaller, and his PET scan was negative. A patient with FL
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(with the last progression following a 14-month response with
bendamustine) achieved complete remission with urelumab
0.3 mg/kg plus rituximab; this response was still ongoing at
56 months at the last follow-up (June 2019). Additionally, the patient
with FL who experienced grade 4 chemical hepatitis after receiving
several doses of urelumab 0.3 mg/kg (the DLT that defined the MTD)
had a partial remission of a large thoracic mass that lasted for
13 months.
3.6 | Pharmacodynamics
Expression of interferon-γ (IFN-γ)-induced genes, including C-X-C
motif chemokine ligand 9 (CXCL9; also known as monokine induced
by IFN-γ) and guanylate binding protein 1 (GBP1), increased after
treatment with urelumab monotherapy and urelumab plus rituximab
(Figure S2A, B). Although samples were limited, a trend was observed
towards greater induction of CXCL9 and GBP1 with urelumab
0.3 mg/kg monotherapy 1 week after the first and/or second dose
and greater induction of GBP1with urelumab 0.3 mg/kg plus rituximab
after cycle one, day 5. Mean expression levels returned to baseline in
samples collected prior to administration of the second dose. Many
cytokines, including CXCL10 (also known as IFN-γ-induced protein
10), were also transiently induced with urelumab monotherapy or
urelumab plus rituximab (Figure S2C). However, due to a limited num-
ber of samples available at baseline for urelumab 0.3 mg/kg, dose
dependency could not be determined. Overall, no association was
observed between peripheral IFN-γ-induced changes and response;
however, correlative analyses were limited by a small sample size.
4 | DISCUSSION
The rationale for evaluation of urelumab in hematologic malignancies
was based on preclinical analyses of human primary lymphomas,
including DLBCL and FL.19 Bulk tumor samples from patients with
lymphoma showed overexpression of CD137 mRNA compared with
nonlymphoma samples and were infiltrated with CD137+ T cells, while
tumor B cells were uniformly negative for CD137.19 The population
of CD137+ tumor-infiltrating T cells may be a source of tumor-
reactive cells that could be stimulated by CD137 agonism.19 More-
over, in murine lymphoma models, anti-CD137 treatment led to
durable antitumor activity as monotherapy.19
In the CA186-011 and CA186-017 phase 1 studies, the safety
and antitumor activity of urelumab alone or in combination with
rituximab were evaluated in patients with solid tumors (CA186-011
only) and B-cell NHL. These studies were designed to assess a lower
urelumab dose range, with a focus on liver toxicities, due to liver
injury and drug-related deaths observed in prior studies that evalu-
ated higher doses of urelumab.16 While the clinical mechanism is
unclear, previously published preclinical data suggest that anti-
CD137-induced liver toxicity may be partially due to infiltration of
S100A4+ macrophages into the liver, following activation of CD8+
T cells and secretion of IFN-γ.24,25 The TRAEs leading to discontinua-
tion included grade 3 increased AST in a patient treated with
urelumab 8 mg Q3W, grade 4 acute hepatitis in a patient treated with
urelumab 0.3 mg/kg, and one death from sepsis syndrome in a patient
treated with urelumab 0.3 mg/kg plus rituximab. The sepsis syndrome
was the only treatment-related death reported in either study.
Overall, the MTD was established as urelumab 0.1 mg/kg or 8 mg
Q3W based on a pDILI reported in one patient treated with urelumab
0.3 mg/kg (CA186-011). Despite this single event, liver toxicity was
less frequent and severe in these studies than previously observed
with higher urelumab doses.16
In the CA186-017 study, urelumab in combination with rituximab
did not enhance clinical activity relative to rituximab alone26,27 or stan-
dard of care.1,3 Although rituximab is generally evaluated in combination
regimens in DLBCL, a previous study of rituximab monotherapy (eight
doses) demonstrated an ORR of 37% in patients with DLBCL, including
patients with R/R disease or those >60 years old without prior
therapy;27 this ORR is higher than that observed with urelumab plus
rituximab in patients with R/R DLBCL in this study (ORR, 10%). More-
over, in previous studies of rituximab monotherapy (four doses) in
patients with R/R FL or low-grade lymphoma, ORRs ranged from 36%
to 48%,26 which are similar to or higher than that observed in patients
with R/R FL treated with urelumab plus rituximab in this study (ORR,
35%). Cross-study comparisons should be interpreted with caution
because the patient populations are different, and the proportion of
patients with prior rituximab treatment in studies CA186-011 and
CA186-017 is likely higher than in the earlier studies noted above. Of
note, the ORR observed in patients with FL treated with urelumab plus
rituximab in this study was similar to that observed with another anti-
CD137 agonist, utomilumab, evaluated in combination with rituximab
(four doses) in patients with rituximab-refractory FL (ORR, 33%
[n = 24, dose escalation] and 44% [n = 9, cohort expansion]).28 Variable
trends of PFS and OS observed in CA186-011 and CA186-017 have
also been reported in studies evaluating recommended regimens for
R/R FL and DLBCL.3
In the CA186-011 and CA186-017 studies, antitumor activity,
including several durable remissions, was observed with urelumab as
monotherapy or in combination with rituximab. However, many of
these responses were observed at doses that exceeded the MTD,
suggesting that the limited clinical activity observed may be due to
suboptimal CD137 agonism. Future studies evaluating next-
generation therapies that target CD137 with unique approaches to
safely increase the dose/exposure of CD137 delivery are under-
way.14,29 Specific approaches include but are not limited to bispecific
antibodies engaging 4-1BB and a tumor antigen/stromal component,
intratumoral delivery, local nanoparticle-anchored antibodies, and/or
unique combination therapies.14,29-32 These strategies may lead to
more efficacious CD137 therapy for patients with R/R B-cell lym-
phoma, a population with a high unmet need.
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